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ABSTRACT 
Combinatory effects of the bioflavonoid apigenin with chemotherapeutic drugs on 
prostate, colon, and lung cancer cell lines 
Lesly Anne J. Lopez 
Lung, prostate, and colon cancer are among the most commonly diagnosed cancers in 
Americans. Current chemotherapeutic regimens generally have toxic side effects leading 
to the death of normal cells.  Polyphenols are naturally occurring compounds that can be 
found in fruits, vegetables and herbs.  Apigenin is a polyphenolic compound that has 
been shown to have antioxidant and anti-inflammatory effects.  In this study, apigenin 
was shown to inhibit the proliferation of several cancer cell lines.  The combination of 15 
uM apigenin and the chemotherapeutic drugs including doxorubicin, etoposide, 
mitomycin C, and 5-fluorouracil significantly decreased (P<0.05) the IC50 to inhibit the 
proliferation of prostate cancer cell lines PC-3 and DU-145 more than the 
chemotherapeutic drugs alone.  Similarly, the addition of apigenin greatly enhanced the 
sensitivity of colon cancer cell lines HCT-116 and colo-205 and lung cancer lines A549 
and H460 to doxorubicin, mitomycin C, 5-fluorouracil, and cisplatin. We analyzed 
sensitivity via cell death and cell proliferation assays.
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Chapter 1: Introduction 
Although two-thirds of human cancers are preventable by lifestyle changes such as 
dietary modifications (Katiyar et al 2001), the American Cancer Society reports that in 
2005, 6.9 million patients will die of cancer and 10.9 million more will be diagnosed 
world wide. In the US alone, 570,000 patients will die of cancer and nearly 1.4 million 
new cases will be diagnosed. The leading cause of cancer death in America is lung cancer 
followed by prostate cancer, with an expected 170,000 and 230,000 new cases to be 
diagnosed. Colon cancer, the third most diagnosed cause of cancer in the US, will see 
about 105,000 new cases in 2005.  
 
Cancer, or the unregulated growth of cells in the body, can manifest itself in many 
forms, but they all start out with damage to the DNA. Treatment varies widely with the 
cancer’s point of origin and can vary within each type depending on the individual. Most 
often, surgery is performed to physically remove the mass of cells. It is most successful 
in cancers that have not yet spread to any other part of the body. The complications 
involved with the surgical removal of cancer are the same with any surgical procedure 
and can include bleeding, damage to internal organs and vasculature, an undesirable 
reaction to anesthesia, and blood clots.  Ionizing radiation is another common method 
employed with cancer treatment. The power of radiation lies in its ability to physically 
target rapidly dividing cells. Since growth patterns of cancer cells are abnormal and 
unregulated, this makes the treatment particularly effective. Radiation can be employed 
with either photons (x-rays or gamma rays) or particle radiation (alpha or beta particles, 
protons, neutrons, electrons), but the complications are many. The treatment can only 
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discriminate between radiosensitive and non-radiosensitive cells but not cancerous and 
noncancerous cells, and commonly kills a number of normal cells in the body. The 
patient undergoing radiation often experiences fatigue and loss of taste, and the patient’s 
skin can undergo peeling and a pigment darkening.  
 
Chemotherapeutic treatments of cancer involve the administration of any number of 
anticancer drugs via oral, intravenous, or vaccine-like administration. The advantages to 
chemotherapy over surgery and ionizing radiation are that does not rely on a trained eye 
to be able to physically discern the cancer before being able to target it, and that it is 
released into the bloodstream where it can then “seek out” the cancer throughout the 
body. Like ionizing radiation, its power lies in its ability to target rapidly dividing cells. 
However, because it works globally throughout the body due to its availability in the 
blood stream, it also affects the body’s high-turnover cells like those in the stomach, 
mouth, hair and nails. Common drugs include doxorubicin and etoposide for the 
treatment of prostate cancer, 5-fluorouracil and platinum-based drugs for the treatment of 
colon cancer, and paclitaxel and vinorelbine for treatment for lung cancer. Combinations 
of chemotherapeutic drugs are common, such as the addition of leucovorin to 5-
fluorouracil, and can lead to less severe side effects.  
 
Immunotherapeutic treatments of cancer involve stimulating the body’s own natural 
defenses against invasion. The power of immunotherapy hinges on the often very 
different characteristics of cancer cells and the body’s ability to recognize these cells as 
abnormal. Treatment can take the form of cancer vaccination, administration of a 
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monoclonal antibody therapy, or a nonspecific immunotherapy regimen that can boost the 
body’s immune system overall. Because immunotherapy is a relatively new technique, 
variety of treatment regimens are slim and little is known yet known about the long-term 
effects.  
Chapter 2:  Review of Literature 
Often, a patient’s treatment regimen includes a combination of techniques. Surgery 
with followed by chemotherapy is a common regimen. Chemotherapeutic drugs affect 
throughout the bloodstream, the drug’s mechanism must be eloquently designed in order 
to affect only cancerous cells. This often means directing the drug towards the unique 
characteristics of cancer cell and the way it can progress through the cell cycle. One 
difference between cancer cells and normal cells is its p53-dependent status. When a 
normal cell has damaged DNA, this signals the tumor-suppressor protein p53 and the cell 
cycle kinase inhibitor p21 to activate (Manic et al 2003). This leads to an arrest of growth 
in the G1 or G2 growth phase of the cell cycle, making it unable to for the damaged cell 
to continue into mitosis (Cui et al 2002). If a particular form of cancer lacks these p53 or 
p21 tumor suppressors, the cell cycle continues on having lacked any signal to turn itself 
off. This leads to a proliferation of DNA-damaged cells.  
 
A potential new cancer treatment also includes targeting the nuclear factor kappa B 
(NF-kappaB) pathway. NF-kappaB has been implicated in regulation of cell growth, 
apoptosis, inflammation and the stress response (Lin et al 2003, Li et al 2002, Karin et al 
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2002). Its involvement on multiple cancers makes it a good target for chemotherapy. The 
PI3K / AKT pathway activates a number of growth factors and cytokines unique to the 
life span of a cancer cell. Its activation promotes cell survival by inhibiting apoptosis by 
inactivating anti-apoptotic factors (Brenet et al 1999, Cardone et al 1998). The 
overexpression of members of this pathway also make it a good target for 
chemotherapeutic drugs. Another target of chemotherapy is the MAPK pathway, a three-
tiered kinase set consisting of MAP3K, MAP2K, and a MAPK, which can be ERK, JNK, 
or p38. When activated, these MAPKs can lead to NF-kappaB, increased cell growth and 
survival (Sebolt-Leopold 2000, Seger and Krebs 1995). These characteristics found in 
cancer cells help make the MAPK pathway a useful target for chemotherapy. 
 
Polyphenols are naturally-occurring antioxidants found in plants that have been 
shown to have effects on biological activity.  Classified as flavonoids, phenolic acids, 
stilbenes, lignans, they are found in red wine, tea, fruits, and vegetables (Kuroda et al 
1999). Recently, their antioxidant properties have been shown play a role in cell survival 
(Chen et al 2000), cell cycle arrest (Yoshida et al 1990, Ranelletti et al 1992, Lepley et al 
1996), and cell cycle enzyme arrest (Formica 1995, Cos et al 1998, Dugas et al 2000, 
Pietta et al 2000). Naturally-occuring compounds like the flavonoids (Fig. 2.1), the most 
abundant group of plant polyphenols, have been recently showed to inhibit tumor growth 
(Formica and Regelson 1995, Kobyashi et al 2002). The chemopreventative effects of 
these flavanoids have been studied in stomach, esophagus, duodenum, pancreas, liver, 
breast, colon, lung, and skin cancers in addition to the elucidation of their role in 
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atherosclerosis, cholesterol, and blood pressure (Nachshon-Kedmi et al 2002, Kim et al 
1998, Kris-Etherton PM & Keen CL 2002). 
 
Flavonoids have four subclasses divisible by structure, and each subclass has a 
number of developing chemotherapeutic drugs (Table 2.1). The flavanols, flavones, 
isoflavones, flavonols, and anthocyanidins have yielded enormous success as pre-clinical 
trial chemotherapeutics (Gao et al 1999, Fotsis et al 1997). The structure of a flavonoid 
itself is comprised of two benzene rings connected by an AC ring, with the C ring and 
C2-C3 double bonds correlating with anti-proliferative activity and apoptosis (Deguchi et 
al 2002, Choi et al 2005, Etherton et al 2002, Gao et al 1999, Gupta et al 2003).  
 
One flavone of interest is apigenin, also known as 4’, 5, 7 trihydroxyflavone (Fig. 
2.2). Apigenin has been classified as a nonmutagenic antioxidant and free radical 
scavenger with low toxicity (Birt et al 1986, Duthie et al 2001). It has been to shown to 
have anti-inflammatory properties in prostate cancer  (Gupta et al 2001, Casagrande and 
Darbon 2001), be able to arrest the cell cycle arrest in colon and prostate cancer (Wang et 
al 2000, Gupta et al 2002) and to slow down growth and metastatic potential in 
melanoma (Caltagrione et al 2000). In neuroblastoma, apigenin has the potential to 
inhibit tumor growth, cell viability and induce caspase-dependent apoptosis in a p53 
dependent manner in neuroblastoma and cervical cancer (Torkin et al 2005, Zheng et al 
2005). Apigenin has also been shown to induce a dose-dependent phosphorylation of 
ERK and p38 kinase but not JNK (Van Dross et al 2003), and to cause endothelial cell 
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death with increasing reactive oxygen species levels via JNK- and p38 MAPK-responsive 
activation (Choi et al 2005).  
 
Previously, our laboratory has shown apigenin to inhibit VEGF / HIF-1 expression 
through the PI3K / AKT and p53 pathways (Fang et al 2004). Previous work from our 
laboratory showed that apigenin affects decreases cell proliferation in PC-3 and DU145 
prostate cancer cells in a dose-dependant manner. Combining apigenin with cisplatin was 
also shown to significantly decrease cell proliferation and increase apoptosis in a 
cisplatin-resistant variant of the A2780 ovarian cancer cell line, CP70, over cisplatin 
alone. 
 
Currently, surgery or radiation combined with chemotherapy is the most common 
treatment of cancer. However, standards of health can decrease due to the toxic effects of 
any of these treatments. Radiation can decrease surfactant production so lungs don’t 
inflate completely or cause stiffening or scarring, a condition called fibrosis. In the 
prostate, sexual dysfunction can occur. A recent development in chemotherapeutics the 
administration of drugs in combination to maximize cancer-killing properties with the 
least amount of non-specific toxicity drugs are now being administered (Calviello et al 
2005). Here, we propose that the non-mutagenic dietary flavanoid apigenin be combined 
with current chemotherapeutic drugs to enhance their effects without additional toxic 
effects.  
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Chapter 3:  Text of Investigation 
In order to determine whether apigenin exerts a sensitizing effect on cancer drugs 
undergoing chemotherapy, we chose a variety of cell lines: the p53 mutant prostate 
cancer cell lines PC-3 and DU-145, the p53 mutant colo-205 and p53 wild-type HCT-116 
colon cancer cell lines, and the p53 wild-type A549 and H460 lung cancer cell lines 
(Table 3.1). 
 
Materials and Methods 
Cell Culture 
PC-3 cells (ATCC  CRL-1435) were grown in RPMI supplemented with 10% fetal calf 
serum, 2 mM L-glutamine and 1 % penicillin/streptomycin. Subcultivation was 
completed every 2-3 days with a 0.025% trypsin solution at a 1:10 ratio.  
DU-145 cells (ATCC HTB-81) were grown in DMEM supplemented with 10% fetal 
bovine serum, 2 mM L-glutamate and 1 % penicillin/streptomycin. Subcultivation was 
done once every 6-7 days with at 0.025% trypsin solution at a 1:5 ratio.  
Colo-205 cells (ATCC CCL-222) were grown in RPMI 1640 supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 
mM  HEPES, 1.0 mM sodium pyruvate, and 1 % penicillin/streptomycin. Subcultivation 
was done every 5-6 days with a 0.025% trypsin solution at a 1:5 ratio. 
HCT-116 cells (ATCC CCL-247) were grown in McCoy’s 5a medium supplemented 
with 10% fetal bovine serum, 1.5 mM L-glutamine, and 1 % penicillin/streptomycin. 
Subcultivation was done every 3-4 days with a 0.025% trypsin solution at a 1:10 ratio.  
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A549 cells (ATCC CCL-185) were grown in RPMI supplemented with 10% fetal calf 
serum, 2 mM L-glutamate and 1 % penicillin/streptomycin. Subcultivation was done 
every 2-3 days with a 0.025% trypsin solution at a 1:6 ratio. 
H460 cells (ATCC HTB-177) were grown in RPMI supplemented with 10% fetal calf 
serum, 2 mM L-glutamate and 1 % penicillin/streptomycin. Subcultivation was done 
every 4-5 days with a 0.025% trypsin solution at a 1:8 ratio. All cells were incubated at 
37 C in a 5% CO2 controlled environment and had their media refreshed every three days. 
 
Drug Treatments 
Chemotherapeutic drugs used include:  doxorubicin hydrochloride, an inhibitor of 
reverse transcriptase and RNA polymerase; cisplatin, a repair mechanism inhibitor; 
etoposide, a DNA cleavage enhancer; mitomycin C, a DNA synthesis and nuclear 
division inhibitor, and 5-fluorouracil, a DNA synthesis inhibitor.  The chemotherapy 
drugs doxorubicin, mitomycin C, etoposide, 5-fluorouracil, and cisplatin as well as the 
flavanol apigenin were all obtained from Sigma Aldrich. 
 
Cell proliferation assays 
Cell proliferation assays were measured via MTT absorption. Cells were plated in 
96-well plates (Corning Life Sciences) at 1x104 cells per well in 100 uL of feeding media 
and were allowed to adhere overnight. The next day, the media was removed and 
replaced with fresh medium or treatment doses. Cells were incubated at 37 C for 24 hours 
before the addition of 10 uL of 5 mg/mL thiozolyl blue tetrazolium bromide reagent 
(Sigma Aldrich). After another 2 hr incubation, the reaction was stopped by adding 100 
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uL of solubilization solution. Measurements were taken using a spectrophotometer at 470 
nm after 4 hours.  
 
Cell Death: 
Cell death was measured via trypan blue exclusion. Cells were plated at 1x106 in 
6 well plates and allowed to adhere overnight. The next day, the plating medium was 
removed and cells were washed with 1x PBS before serum starving for 8 hours. The 
media was then refreshed and drug treatments administered for 6 hours. The cells were 
then washed with 1x PBS, detached with 0.025% trypsin, spun at 2000 RPM at 4 C for 5 
minutes, aspirated, and resuspended in 1 mL 1x PBS. An aliquot of this suspension was 
then stained with an equal volume of trypan blue (Gibco-BRL) and counts of live and 
dead cells were done using a hematocytometer.  
 
Statistical Analysis 
Significant differences were calculated using ANOVA with p<0.05. IC50’s were 
calculated using a regression calculation. 
 
Chapter 4:  Summary and Conclusions 
Summary 
Effects of Apigenin on Different Cell Types 
To study the effect of apigenin on cell proliferation, the cells were treated with 
apigenin at various doses. In PC-3 and DU-145 cell lines, 10 uM or higher of apigenin 
alone significantly decreased cell proliferation (P<0.05, Fig. 4.1). The apigenin has 
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similar inhibitory effects on colon cancer cell lines.  The apigenin treatment at 15 uM 
significantly decreased cell proliferation in colo-205 and HCT-116 (Fig. 4.2). HCT-116 
cells were much more sensitive to 15 and 20 uM of apigenin. The effects of apigenin are 
similarly observed in other human cancer cells including A549 and H460 cells (Fig. 4.3). 
 
The Combination effects of Apigenin with Chemotherapy Drugs 
Doxorubicin: To study the effect of apigenin combined with doxorubicin on cell 
proliferation, PC-3 cells were treated by doxorubicin alone or in combination with 15 uM 
apigenin. Our data showed that apigenin treatment alone greatly decreased cell 
proliferation (Fig. 4.4a). We used a similar method to treat DU-145 cells and found that 
apigenin treatment alone was sufficient to inhibit cell proliferation and the addition of 
doxorubicin did not further enhance the effect (Fig. 4.4b). For colon cancer cell lines, the 
combination treatment of apigenin and doxorubicin has synergistic or additive effects to 
inhibit cell proliferation, especially Colo-205 cells (Fig. 4.4c). However, there were no 
significant differences with or without the drug treatment in A549 and H460 cells when 
combined with apigenin (Fig. 4.4d).  
 
Etoposide: With etoposide treatment in prostate cancer cells, PC-3 (Fig. 4.5a) 
cells seemed more sensitive to drug treatment with and without apigenin that did the DU-
145 (Fig. 4.5b).  
 
Mitomycin C: To study the effect of apigenin combined with the 
chemotherapeutic drug mitomycin C, we observed that low doses of mitomycin C were 
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sufficient to inhibit cell proliferation in either PC-3 or DU-145 prostate cancer cell lines 
and the addition of apigenin increased sensitivity of the cells to mitomycin C (Fig. 4.6a).  
In the colon cancer cell lines colo-205 and H460, the effects  of the combination therapy 
between mitomycin C and apigenin has significantly higher inhibitory effect that 
mitomycin C alone(Fig. 4.6b).  
 
Similarly in A549 and H460 lung cancer cell lines, the combination treatment 
between mitomycin C and apigenin has significantly higher inhibitory effect than 
mitomycin C alone (Fig. 4.6c).  Although both showed a significant decrease in cell 
proliferation when treating with mitomycin C alone, the inhibitory effect on H460 cell 
lines is nearly two-fold stronger than that in A549 cells.  
 
5-Fluorouracil: In PC-3 and DU-145 cells, the combination treatment of 
apigenin and 5-fluoruracil alone significantly decreased cell proliferation compared to the 
5-fluorouracel alone (Fig. 4.7a).  Similarly, the combination treatment of apigenin and 5-
fluorouracil significantly decreased colo-205 colon cancer cells at 5 and 10 uM than with 
5-fluorouracil alone (Fig. 4.7b). The HCT-116 in comparison were much more sensitive 
when treated by the combination of apigenin and 5-fluorouracil (Fig. 4.7c)  
 
Cisplatin: The combination treatment of apigenin and cisplatin significantly 
decreased cell proliferation at 0.5 and 1 uM cisplatin (Fig. 4.8a). In both colo-205 and the 
HCT-116, the synergistic inhibitory effect was no longer observed when the cells were 
treated by cisplatin at 5 and 10 uM (Fig. 4.8a). In H460 lung cancer cells, significant 
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differences in cell proliferation were observed by the combination treatment than 
cisplatin alone (Fig. 4.8b). However, the combination of apigenin and cisplatin did not 
significantly affect cell proliferation in A549 cells (Fig. 4.8b).   
 
Conclusions 
1.  Apigenin, when combined with a range of chemotherapeutic drugs, can increase 
the sensitivity of prostate, colon, and lung cancer cells to halt cell proliferation.  
 
Apigenin has been shown previously to be a non-mutagenic, low toxicity 
compound, but it is important to keep in mind that each type of cancer would react 
differently to treatment with it, as evidenced by the range in IC50 values as described in 
Fig. 4.9. Here, apigenin’s ability to increase a cell line’s sensitivity to a particular 
chemotherapeutic was measured by its ability to lower IC50 threshold. Based on the 
ranges in response, apigenin’s ability to sensitize depends on cell type. While PC-3 cells 
show significant differences in combination treatment over doxorubicin, 5-fluorouracil 
and mitomycin C treatment alone over DU-145 cells at a range of doses (Fig. 4.4a, 4.4b, 
4.6a, 4.6b, 4.7a, and 4.7b), neither the PC-3 nor the DU-145 IC50 were significant (Fig. 
4.10a and 4.10b). However, etoposide treatment in both PC-3 and DU-145 cells showed 
significant differences in IC50 values (Fig. 4.12a and 4.12b). Similarly, while colo-205 
and HCT-116 showed significant differences in combination treatment over single drug 
treatment over a range of doses for a number of drugs, significant differences in IC50 
values were only seen in doxorubicin and mitomycin C for both and 5-fluorouracil for 
HCT-116 (Fig. 4.10c and 4.10d). In lung cancer cells, significant differences in 
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combination treatment not seen with single drug treatment in A549 and H460 cells were 
found cisplatin and mitomycin C treatment (Fig. 4.10e and 4.10f).  
 
2.  When combined with apigenin, IC50 values of potentially toxic 
chemotherapeutics on some prostate, lung, and colon cancer cell lines decreased 
significantly.  
 
A standard measure of how toxic a particular drug is to an organism is its IC50 
value, or the dosage that would be required to kill off have the cells. Here, we measured 
IC50 values using cell proliferation. As noted by Figures 4.9 - 4.11 and Table 4.1, there is 
a range in how much a drug would be required to hit the IC50 value from cell line to cell 
line. However, in most cases, the addition of apigenin alone seemed to significantly 
decrease amount of chemotherapeutic drug required to kill off half the cells (Fig. 4.9). 
Apigenin combined with doxorubicin exerted the greatest change over drug alone on 
IC50 values on PC-3, A549, and H460 cells (Fig. 4.10a), and mitomycin C exerted the 
greatest change over drug alone on colon and lung cancer lines (Fig. 4.10b). When 
combined with 5-fluorouracil, apigenin showed the greatest effect on IC50 values on 
HCT-116 and A549 cells (Fig. 4.10c), and combined with cisplatin, it showed the 
greatest effect on DU-145 and colo-205 cells (Fig. 4.10d). On IC50 values from 
etoposide treatment, apigenin exerted significantly different effects in combination on 
both PC-3 and DU-145 prostate cancer cell lines. 
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The possibility of using apigenin in combination is promising. Many naturally-
occurring phenolic compounds are now being to see how their antioxidant effects could 
prove useful in decreasing the amount of toxins one must administer in order to undergo 
chemotherapy regimens successfully, such as genestein and (-) epigallocatechin-3-gallate. 
Apigenin’s properties as an anti-inflammatory make it also intriguing in the realm of 
creating new, safe supplements to treat or manage cardiovascular health. Because of its 
ability to create the same clinical effect with a reduced amount of chemotherapy and its 
ability to potentially treat resistant forms of cancer, apigenin’s involvement in a number 
of pathways implicated in variety of cancers makes it an intriguing addition to the recent 
focus on nutriceuticals. 
 
Chapter 5:  Recommendations 
 In order to get a more accurate picture of how cancer cells respond to sensitivity 
to chemotherapeutics when treated with apigenin, further experiments should be carried 
out in normal non-cancerous prostate, lung, and colon cell lines. A comparison of these 
cell types to the cancerous variants would give a more complete indication of whether 
significant differences of cell proliferation could be seen. 
  
 Here, cell death was measured by trypan blue exclusion. For distinction between 
apoptosis and necrosis in measures of cell death, more accurate measures of apoptotic 





Birt DF, Walker B, Tibbels MG and Breskinck E. Antimutagenesis and anti-promotion 
by apigenin, robinetin and indole-3-carbinol. Carcinogenesis 7: 959-963. 1986.  
 
Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FB, and 
Piantelli S. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic 
potential. Int J Cancer 87: 595-600. 2000. 
 
Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N, Ranelletti 
FO, and Palozza P. Docosahexaenoic acid enhances the susceptibility of human 
colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharacol 55:12-20. 2005.  
 
Casagrande F and Darbon JM. Effects of structurally related flavonoids on cell cycle 
progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and 
CDK1. Biochem Pharmacol 2001; 61: 1205-15.  
 
Chen C, Yu R, Owuor ED, and Kong AN. Activation of antioxidant-response element 
(ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea 
polyphenol components during cell survival and death.  Arch Pharm Res 23: 605-12. 
2000. 
 
Choi YJ, Jeong YJ, Kwon HM, and Kang YH. (-) Epigallocatechin gallate and quercetin 
enhance survival signaling in response to oxidant-induced human endothelial apoptosis. J 
Nutr 135: 707-13. 2005.  
 
Cui H, Schroering A, and Ding HF. P53 mediate DNA damaging drug-induced apoptosis 
through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Cancer 
Ther 2002; 1: 679-86.  
 
Deguchi H, Fujii T, Nakagawa S, Koga T, Shirouzu K. Analysis of cell growth inhibitory 
effects of catechin through MAPK in human breast cancer cell line T47D. Int J Oncol 21: 
1301-1305. 2002. 
 
Duthie G, and Crozier A. Plant-derived phenolic antioxidants. Curr Opin in Clin Nutr and 
Metab Care 3, 447-451. 2000. 
 
Fotsis T, Pepper MS, Aktas E, Breit S, Raksu S, Adlecreutz H, Wahala K, Montesano R 
and Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in 
vitro angiogenesis. Cancer Res. 57: 2916-21. 1997.  
 
Gao Z, Huang K, Yang X & Xu H. Free radical scavenging and antioxidant activities of 
flavonoids extracted from the rasix of Scutellaria baicalensis. Georgi Biochim Biophys 
Acta 1472: 643-650. 1999.  
 
 B
Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in 
induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma 
cells. Oncogene 21: 3727-38. 2002. 
 
Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-) epigallocatechin-3-gallate-
induced apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410: 177-
85. 2003.  
 
Katiyar SK, Afak F, Perez A, and Mukhtar H. Green tea polyphenol (-)-epigallocatechin-
3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress, 
Carcinogenesis 22 (2001) 287-294.  
 
Kim HP, Mani I, Iversen L, and Ziboh VA. Effects of naturally-occurring flavonoids and 
bioflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. 
Prostagland, Leuko, and Essen Fatty Acids 58: 17-24. 1998. 
 
Kobyashi T, Nakata T, and Kuzumakia T. Effect of flavonoids on cell cycle progression 
in prostate cancer cells. Cancer Lett 2002:176:17-23. 
 
Kris-Etherton PM & Keen CL. Evidence that the antioxidant flavonoids in tea and cocoa 
are beneficial for cardiovascular health. Curr Opin Lipidol 13: 41-49. 2002. 
 
Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, and Perego P. Mechanisms 
controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.  
Curr Cancer Drug Targets 3: 21-29. 2003. 
 
Nachshon-Kedmi M, Yannai S, Haj A, and Fares FA. Indole-3-carbinol and 3,3’-
diindolymethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 
41: 745-52. 2003. 
 
Sarkar FH, Li Y. Cell signaling pathways altered by natural chemopreventative agents. 
Mutation Research 555: 53-64. 2004. 
 
Sebolt-Leopold. Development of anticancer drugs targeting the MAPK pathway. 
Oncogene 19: 6594-99. 2000.  
 
Seger R and Krebs EG. The MAPK signaling cascade. FASEB J 9: 726-33. 1995.  
 
Torkin R, Lavoie JF, Kaplan DR, and Yeger H. Induction of caspase-dependent, p53-
mediated apoptosis by apigenin in human neuroblastoma. Mol. Cancer Ther 4(1). 2005.  
 
Van Dross R, Xue Y, Knudson A, and Pelling JC. The chemopreventative bioflavonoid 
apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma 
cell lines. J Nutr 133: 3800S-3804S. 2003.  
 
 C
Wang W, Heiderman L, and Chung CS. Cell-cycle arrest at G2/M and growth inhibition 
by apigenin in human colon carcinoma cell lines. Mol Carciong 2000: 28: 102-10. 
 
Zheng PW, Chiang LC, and Liu CC. Apigenin induced apoptosis through p53-dependent 









Appendix: Figure Legend 
 
Table 2.1. Subclasses of flavonoids involved in cancer signaling pathways.   
 
Flavanoids are naturally-occuring polyphenol compounds with antioxidant properties. 
Many have been implicated to be involved in cell signaling pathways. 
 
Flavonols myricetin, quercetin 
Flavones apigenin, luteolin 
Isoflavones genistein, luteone 
Flavonones hesperiden, pinocembrin 
Flavanols epicatechin 








Table 3.1. Characterization of cell lines. 
 
The PC-3 and DU-145 prostate cancer cell line as well as the Colo-205 colon cancer cell 
line have been characterized as having a mutant p53 tumor suppressor status, and 
therefore is unable to halt damaged DNA from going through the cell cycle. The HCT-
116 colon cancer cell line as well as the A549 and H460 lung cancer cell line has been 












Cell line P53 status Origin 
Wild-type Epithelial lung 
carcinoma 
Wild-type Epithelial colorectal 
carcinoma 











Table 4.1. IC50 values of cell lines. 
 

















Figure 2.1. The structure of flavonoids. 
 
The general structure of a flavonoid is comprised of two benzene rings joined by an AC 
ring. Certain structural characteristics of flavonoids have been shown to have 







Figure 2.2. The structure of apigenin. 
 
Apigenin, also known as 4’, 5, 7 trihydroxyflavone, is a polyphenolic compound that is 
found in fruits, vegetables, herbs, and a host of other natural sources. It is classified in the 









Figure 4.1. Response of prostate cancer cell lines PC-3 and DU-145 to apigenin. 
 
PC-3 and DU-145 cells were plated at 1x104 cells per well in a 96 well plate in 100 uL of 
media. They were treated with drug in fresh media for 24 hours. 10 uL of MTT reagent 
(thiozolyl blue tetrazolium) was added to each well before incubating for another 2 hours. 












































Figure 4.2. Response of colon cancer cell lines colo-205 and HCT-116 to apigenin. 
 
Colo-205 and DU-145 cells were plated at 1x104 cells per well in 100 uL media for a 24 
hour drug treatment time. 10 uL of MTT reagent was added to each well before 
incubating for another two hours. Results were read using a spectrophotometer at 470 







Figure 4.3. Response of lung cancer cell lines A549 and H460 to apigenin. 
 
While both A549 and H460 lung cancer cells decreased cell proliferation significantly, 




Figure 4.4. Apigenin induced sensitivity of prostate, lung, and colon cancer cell lines 
to doxorubicin. 
 
Over a range of doses, PC-3 cells (Fig. 4.4a) treated with apigenin seemed to be more 
sensitive to doxorubicin treatment than DU-145 cells (Fig. 4.4b), colo-205 cells seemed 
more sensitive at lower doses than HCT-116 cells (Fig. 4.4c), and both A549 and H460 







Figure 4.5. Apigenin induced sensitivity of the PC-3 and DU-145 prostate cancer cell 
lines to etoposide. 
 
PC-3 cells showed a marked sensitivity to etoposide when treated with apigenin in cell 
proliferation assay (Fig. 4.5a). DU-145 cells showed more drug resistance to etoposide 






Figure 4.6. Apigenin induced sensitivity of the prostate, colon, and lung cancer cell 
lines to mitomycin C. 
 
Both PC-3 and DU-145 cells showed sensistivity to mitomycin C when treated with 
apigenin and measured by cell proliferation assay (Fig. 4.6a). Both colo-205 and HCT-
116 exhibit apigenin-induced sensitivity, however, HCT-116 cells exhibit a much greater 
sensitivity (Fig. 4.6b). Although both showed a significant decrease in cell proliferation 
when treating with mitomycin C and apigenin over mitomycin C alone, the H460 cell 




Figure 4.7. Apigenin induced sensitivity of the prostate, colon, and lung cancer cell 
lines to 5-fluorouracil. 
 
Both PC-3 and DU-145 cell lines exhibited a decrease in cell proliferation, but only the 
PC-3 cells did so consistently in a dose-dependent fashion (Fig. 4.7a). While both the 
colo-205 (Fig. 4.7b) and HCT-116 (Fig. 4.7c) cells showed a decrease in cell 




Figure 4.8. Apigenin induced sensitivity of colon and lung cancer cell lines to 
cisplatin. 
 
Apigenin does help increase sensitivity to cisplatin treatment in colon cell proliferation, 
but only below 5 uM doses (Fig. 4.8a). Like colon cancer cells, lung cancer cells show 






Figure 4.9. IC50’s of prostate, colon, and lung cancer cell lines. 
 
The IC50 value, or the dosage at which half the cells in treatment die, vary from cell type 
to cell type. HCT-116 has the highest tolerance for apigenin, while PC-3 and A549 cells 





Figure 4.10. Comparison of IC50 response to chemotherapeutics with and without 
apigenin by drug type. 
 
Apigenin treatment shows the greatest response on IC50 values in PC-3 and DU-145 
cells treated with etoposide (Fig. 4.10a and 4.10b), in colo-205 cells treated with 5-
fluorouracil (Fig. 4.10c), HCT-116 cells treated with mitomycin C (Fig. 4.10d), A549 






Figure 4.11. Comparison of IC50 response to chemotherapeutics with and without 
apigenin by cell line. 
 
Response on doxorubicin (Fig. 4.11a), mitomycin (Fig. 4.11b), 5-fluorouracil (Fig. 




Figure 4.12. Apigenin induced sensitivity of the PC-3 and DU-145 prostate cancer 
cell lines to etoposide.  
 
Both PC-3 and DU-145 prostate cancer cells showed a significant response when treated 
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